Rebound insomnia: a new clinical syndrome.
Rebound insomnia followed the withdrawal of three benzodiazepine hypnotic drugs, each of which had been administered in a single nightly dose for only short-term periods. The intense worsening of sleep is attributed to the short duration of the action of these drugs. A hypothesis involving benzodiazepine receptors in the brain is proposed in which there is a delay or lag in replacement of endogenous benzodiazepine-like molecules after the abrupt withdrawal of exogenous drugs.
D001569:Benzodiazepines / Q000009:adverse effects* / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D005445:Flunitrazepam / Q000009:adverse effects / Q000378:metabolism; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects* / Q000378:metabolism; D009567:Nitrazepam / Q000009:adverse effects / Q000378:metabolism; D011955:Receptors, Drug / Q000187:drug effects / Q000378:metabolism; D007319:Sleep Initiation and Maintenance Disorders / Q000209:etiology* / Q000378:metabolism; D013375:Substance Withdrawal Syndrome / Q000378:metabolism; D013577:Syndrome; D013997:Time Factors; D014229:Triazolam / Q000009:adverse effects / Q000378:metabolism
D006993:Hypnotics and Sedatives; D011955:Receptors, Drug; D001569:Benzodiazepines; D014229:Triazolam; D005445:Flunitrazepam; D009567:Nitrazepam